A manufacturer of a Schedule II product entered into sequential patent settlement agreements that included product supply obligations. Following allegations from its partners that the manufacturer was using the patent settlements to adversely affect competition, CRA’s analysis demonstrated that there was no anticompetitive effect and that the supply agreements enhanced efficiency and competition, particularly when considering the Drug Enforcement Agency’s quota system for active ingredient supply for Schedule II products.
Keler Marku joins CRA's Antitrust & Competition Practice
“We are pleased to welcome Keler back to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Keler is an expert in...